secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-102489
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences reports positive interim SGT-003 data; microdystrophin expression 60% at Day 90, 91% at Day 360
--------------------------------------------------------------------------------

- 40 participants dosed; SGT-003 well tolerated with steroid-only immunomodulation regimen.
- Day 90 biopsy (n=20): mean microdystrophin expression 60% (western blot), 63% positive fibers; 60% beta-sarcoglycan restoration.
- Day 360 biopsy (n=3): microdystrophin expression 91% (western blot), 69% positive fibers; 69% beta-sarcoglycan restoration.
- Biomarker improvements: CK -38%, ALT -43%, AST -30%, LDH -46%, eMHC -44% at Day 90.
- FDA aligned on Phase 3 design; screening underway; first participant dosing expected Q1 2026; accelerated approval discussions planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312526102489/0001193125-26-102489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312526102489/sldb-20260311.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-102489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer